Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

T. Jake Liang; John L.M. Law; Thomas Pietschmann; Stuart C. Ray; Jens Bukh; Rowena Bull; Raymond T. Chung; D. Lorne Tyrrell; Michael Houghton; Charles M. Rice

doi:10.1093/cid/ciad336

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

T. Jake Liang, John L.M. Law, Thomas Pietschmann, Stuart C. Ray, Jens Bukh, Rowena Bull, Raymond T. Chung, D. Lorne Tyrrell, Michael Houghton, Charles M. Rice

School of Medicine

Research output: Contribution to journal › Article › peer-review

Abstract

For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

Original language	English (US)
Pages (from-to)	S257-S261
Journal	Clinical Infectious Diseases
Volume	77
DOIs	https://doi.org/10.1093/cid/ciad336
State	Published - Aug 15 2023

Keywords

acute hepatitis
risk-benefit analysis
treatment
vaccine development

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

Access to Document

10.1093/cid/ciad336

Cite this

@article{6d20e2abd0ba40ada3df687b10b11897,

title = "Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model",

abstract = "For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.",

keywords = "acute hepatitis, risk-benefit analysis, treatment, vaccine development",

author = "Liang, {T. Jake} and Law, {John L.M.} and Thomas Pietschmann and Ray, {Stuart C.} and Jens Bukh and Rowena Bull and Chung, {Raymond T.} and Tyrrell, {D. Lorne} and Michael Houghton and Rice, {Charles M.}",

year = "2023",

month = aug,

day = "15",

doi = "10.1093/cid/ciad336",

language = "English (US)",

volume = "77",

pages = "S257--S261",

journal = "Clinical Infectious Diseases",

issn = "1058-4838",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

AU - Liang, T. Jake

AU - Law, John L.M.

AU - Pietschmann, Thomas

AU - Ray, Stuart C.

AU - Bukh, Jens

AU - Bull, Rowena

AU - Chung, Raymond T.

AU - Tyrrell, D. Lorne

AU - Houghton, Michael

AU - Rice, Charles M.

PY - 2023/8/15

Y1 - 2023/8/15

N2 - For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

AB - For any controlled human infection model (CHIM), a safe, standardized, and biologically relevant challenge inoculum is necessary. For hepatitis C virus (HCV) CHIM, we propose that human-derived high-titer inocula of several viral genotypes with extensive virologic, serologic, and molecular characterizations should be the most appropriate approach. These inocula should first be tested in human volunteers in a step-wise manner to ensure safety, reproducibility, and curability prior to using them for testing the efficacy of candidate vaccines.

KW - acute hepatitis

KW - risk-benefit analysis

KW - treatment

KW - vaccine development

UR - http://www.scopus.com/inward/record.url?scp=85168210876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85168210876&partnerID=8YFLogxK

U2 - 10.1093/cid/ciad336

DO - 10.1093/cid/ciad336

M3 - Article

C2 - 37579208

AN - SCOPUS:85168210876

SN - 1058-4838

VL - 77

SP - S257-S261

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

ER -

Challenge Inoculum for Hepatitis C Virus Controlled Human Infection Model

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this